Stephen Myatt

Witham Contract Manufacturing Ltd. manufactures and distributes pharmaceutical and healthcare products. It offers natural, botanical and plant extracts for the food, drink, pharmaceutical and related industries. The company was founded on December 23, 1912 and is headquartered in Southampton, the United Kingdom.

De Novo Pharmaceuticals Ltd. discovers and develops drugs. It is a novel molecular structure generating drug discovery platform targeting pathogenic bacteria. The firm offers lower cost, rapid, lower molecular weights hits, novel, and patentable hit molecules. The company was founded by David Bailey, Iwan de Esch, and Philip Dean M on April 28, 1999 and is headquartered in London, the United Kingdom.

Oxford Immunotec Ltd. operates as a medical diagnostic company. It develops and sells medical diagnostic products. The company was founded by Peter Wrighton-Smith in 2002 and is headquartered in Abingdon, the United Kingdom.

Molten Ventures (Private Equity) (Molten Ventures) is a venture capital firm subsidiary of Molten Ventures Plc founded in 1998 by Simon Christopher Cook and Stuart Malcolm Chapman. The firm is headquartered in London, United Kingdom.

Crawford Healthcare Ltd. develops, manufactures, and supplies dermatological, woundcare, and diagnostic products. It offers SunSense, QV, SilDerm, Cuplex, Chemotechnique, Zindaclin, ViTix and ViTicolor, and Chemo Nickel and Cobalt test. The company was founded in 1996 and is headquartered in Knutsford, the United Kingdom.

NeoPhore Ltd. engages in discovery and development of small molecules inhibitors to treat cancer. The company is headquartered in Kings Cross, London, the United Kingdom.

Adorx Therapeutics Ltd. provides biotechnology, health care and therapeutics services. The company is headquartered in Edinburgh, the United Kingdom.

Invivo Capital Partners SGEIC SA (Invivo Capital Partners) is a venture capital firm founded in 2019 by Albert Ferrer and Luis Pareras. The firm is headquartered in Barcelona, Spain.

Pulmobiotics SL operates as a spin off company. The firm uses its technology to discover and develop novel treatments and vaccines for respiratory diseases. The company was founded by Maria Lluch and Lluis Serrano and is headquartered in Barcelona, Spain.

Leucid Bio Ltd. is a clinical-stage biotechnology company based in London, UK. The British company develops novel, lateral car cell therapies for the treatment of refractory cancers, with a focus on developing next-generation cell therapies for the benefit of individuals with hard-to-treat solid tumors. The company's operations are based at Guys Hospital, enabling them to maintain a patient-centric focus. Leucid's goal is to develop CAR-T therapies with more durable responses, improving treatment outcomes and saving the lives of patients with refractory cancers. Leucid was established to translate 20 years of Kings College research in the CAR-T field and is led by a highly experienced management team, including scientific founder John Maher. Filippo Joseph Petti has been the CEO of the company since 2023.

Gyala Therapeutics SL develops CAR-T therapies for treating hematological malignancies. The company is based in Barcelona, Spain. Claudio Santos has been the CEO of the Spanish company since 2020.